As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.
7 Analysts have issued a Organovo Holdings, Inc. forecast:
7 Analysts have issued a Organovo Holdings, Inc. forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | 0.14 0.14 |
100%
100%
|
|
| Gross Profit | 0.14 0.14 |
250%
250%
|
|
| EBITDA | -12 -12 |
15%
15%
|
|
| EBIT (Operating Income) EBIT | -12 -12 |
15%
15%
|
|
| Net Profit | -1.99 -1.99 |
86%
86%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Organovo Holdings, Inc. engages in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary NovoGen Bioprinters and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company was founded on January 30, 2012 and is headquartered in San Diego, CA.
| Head office | United States |
| CEO | Keith Murphy |
| Founded | 2012 |
| Website | organovo.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


